RNA sequencing reveals novel oncogenic fusions and depicts detailed fusion transcripts of FN1-FGFR1 in phosphaturic mesenchymal tumors.

[1]  Y. Okuno,et al.  Case report: Novel NIPBL-BEND2 fusion gene identified in osteoblastoma-like phosphaturic mesenchymal tumor of the fibula , 2023, Frontiers in Oncology.

[2]  T. Soejima,et al.  Spindle cell sarcoma with KIAA1549-BRAF resembling infantile fibrosarcoma morphologically: A case report and literature review , 2022, Oncology letters.

[3]  Yanmei Zhang,et al.  Fibroblast growth factor receptor fusions in cancer: opportunities and challenges , 2021, Journal of experimental & clinical cancer research : CR.

[4]  Zhi-wen Zhang,et al.  Next-generation sequencing revealed recurrent ZFPM1 mutations in encapsulated papillary carcinoma of the breast , 2021, npj Precision Oncology.

[5]  Jessica L. Davis,et al.  Novel BRAF gene fusions and activating point mutations in spindle cell sarcomas with histologic overlap with infantile fibrosarcoma , 2021, Modern Pathology.

[6]  Yuehua Wu,et al.  Calcified chondroid mesenchymal neoplasms with FN1-receptor tyrosine kinase gene fusions including FGFR2, FGFR1, MERTK, NTRK1, and TEK: a molecular and clinicopathologic analysis , 2021, Modern Pathology.

[7]  Carole B. Miller,et al.  Targeted FGFR Blockade for the Treatment of Tumor-Induced Osteomalacia. , 2020, The New England journal of medicine.

[8]  D. Donoghue,et al.  Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma. , 2019, Cytokine & growth factor reviews.

[9]  A. Folpe,et al.  Frequent overexpression of klotho in fusion-negative phosphaturic mesenchymal tumors with tumorigenic implications , 2019, Modern Pathology.

[10]  A. Flanagan,et al.  Synovial chondromatosis and soft tissue chondroma: extra-osseous cartilaginous tumours defined by FN1 gene rearrangement , 2019, Modern Pathology.

[11]  Yongheng Chen,et al.  Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors , 2019, Cells.

[12]  J. Schittenhelm,et al.  Oncogenic BRAF Alterations and Their Role in Brain Tumors , 2019, Cancers.

[13]  P. A. Futreal,et al.  Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS , 2019, Modern Pathology.

[14]  M. Bui,et al.  Phosphaturic mesenchymal tumor with an admixture of epithelial and mesenchymal elements in the jaws: clinicopathological and immunohistochemical analysis of 22 cases with literature review , 2018, Modern Pathology.

[15]  Y. Oda,et al.  Histopathological and genetic review of phosphaturic mesenchymal tumours, mixed connective tissue variant , 2018, Histopathology.

[16]  J. Otlewski,et al.  The autoinhibitory function of D1 domain of FGFR1 goes beyond the inhibition of ligand binding. , 2017, The international journal of biochemistry & cell biology.

[17]  A. Folpe,et al.  Characterization of FN1–FGFR1 and novel FN1–FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors , 2016, Modern Pathology.

[18]  M. Varella‐Garcia,et al.  KIAA1549: BRAF Gene Fusion and FGFR1 Hotspot Mutations Are Prognostic Factors in Pilocytic Astrocytomas , 2015, Journal of neuropathology and experimental neurology.

[19]  A. Folpe,et al.  Identification of a novel FN1–FGFR1 genetic fusion as a frequent event in phosphaturic mesenchymal tumour , 2015, The Journal of pathology.

[20]  Jing Ma,et al.  Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas , 2009, The Journal of pathology.

[21]  E. Montgomery,et al.  Most Osteomalacia-associated Mesenchymal Tumors Are a Single Histopathologic Entity: An Analysis of 32 Cases and a Comprehensive Review of the Literature , 2004, The American journal of surgical pathology.

[22]  C. Giannini,et al.  Pilocytic astrocytoma: pathology, molecular mechanisms and markers. , 2015, Acta neuropathologica.